Ruxolitinib (5 mg)

ZZZZ_Status (Active, Disc) : Active

 

AA_Supplier Name : Biosensis

 

Alternative_Name (Other Names) :

INCB018424; CAS #:941678-49-5; INCB-018424

 

Antibody_Isotype
(Antibody only) :

 

Application_Details :

Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.

 

Background_Info : Ruxolitinib dihydrochloride is a specific inhibitor of Janus-associated kinase (JAK1 and JAK2). Ruxolitinib is a small molecular with the formula of C17H21N6O4Pand Molecular Weight of 404. Ruxolitinib phosphate is an administered ATP-competitive cyclopentylpropionitrile derivative and shows inhibition activity on JAK1 and JAK2. Ruxolitinib inhibits phosphorylation of JAK1/2, STAT5, and ERK1/2, resulting in reduced cellular proliferation

 

Clone_Name
(AB only, monoclonals) :

 

Datasheet_Link : https://www.biosensis.com/pdf_datasheet.php?products_id=1827

 

Description (Long Description) : 

Pharmacology: Potent and selective JAK1&2 inhibitor, IC50s=2.7, 4.5 and 322 nM for JAK1, JAK2 and JAK3 respectively (1). Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM) (2). Inhibits the proinflammatory secretome of senescent cells (3). The JAK1 S646P mutant is sensitive to ruxolitinib (4). Clinically useful anticancer agent. PubChem CID: 2512798 Product is sold for research use only. Not for human therapeutic use or for medicinal purposes

 

Expiry_Date : 

See storage conditions.

 

Format (Form) : 

Dry powder; Off-white powder

 

Immunogen (Antigen) :306.4 g/mol. Molecular F306.4ormula: C17H18N6

 

Kit_Components :

 

MSDS (File name) :https://www.biosensis.com/pdf_MSDS.php?products_id=1827